IDP-023 treatment for advanced blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates IDP-023, an allogeneic NK cell therapy, administered alone and in combination with antibody therapies like isatuximab, daratumumab, and rituximab in patients with advanced hematologic cancers. The study is structured in two phases: a Phase 1 dose escalation to assess safety and determine optimal dosing, followed by a Phase 2 expansion to evaluate efficacy in patients with relapsed or refractory multiple myeloma and non-Hodgkin lymphoma. The trial aims to gather data on the safety, tolerability, and preliminary antitumor activity of these treatments.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy.
* For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Life expectancy of greater than 12 weeks per the Investigator.

Key Exclusion Criteria:

* Impaired cardiac function or history of clinical significant cardiac disease.
* Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
* Active SARS-CoV-2 infection.
* Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.

Where it's running

• Valkyrie Clinical Trials
  Los Angeles, California, United States Recruiting
• Emory University Hospital
  Atlanta, Georgia, United States Recruiting
• University of Minnesota
  Minneapolis, Minnesota, United States Recruiting
• Atrium Health Wake Forest Baptist
  Winston-Salem, North Carolina, United States Recruiting
• University Hospitals Cleveland
  Cleveland, Ohio, United States Recruiting
• Rhode Island Hospital
  Providence, Rhode Island, United States Recruiting

Study contacts

• Study coordinator: Indapta Therapeutics, Inc.
• Email: TRIALS@INDAPTA.COM

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Talquetamab combined with iberdomide and dexamethasone for relapsed or refractory multiple myeloma

  This phase 1 trial will test whether adding iberdomide and dexamethasone to talquetamab helps people with relapsed or refractory multiple myeloma who have already received proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06348108

• DC/MM fusion vaccine plus BCMA CAR-T for relapsed or refractory multiple myeloma

  This trial will test whether adding a personalized DC/MM fusion vaccine (with GM‑CSF) to standard BCMA CAR‑T therapy helps people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07377435

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Personalized dendritic cell–myeloma fusion vaccine combined with elranatamab for relapsed or refractory multiple myeloma

  This will try a personalized dendritic cell–myeloma fusion vaccine given with elranatamab in people with relapsed or refractory multiple myeloma.

  Recruiting at 2 sites Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts and 1 other locations · NCT06799026

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.